The value of miR-155 expression in predicting early and long-term outcome of coronary artery bypass grafting surgery

miR-155表达在预测冠状动脉旁路移植术早期和长期预后中的价值

阅读:1

Abstract

BACKGROUND: The role of the expression of micro ribonucleic acid-155 (miR-155) in the modulation of inflammatory processes leading to the development of arterial atherosclerosis has been studied, but it is still not clear whether the change in the expression of miR-155 can predict the outcomes after the vascularization procedure. OBJECTIVE: We assessed the value of assessing preoperative miR-155 expression for determining the severity of coronary artery involvement and then determined the association of the expression of this micro ribonucleic acid (microRNA) and poorer outcome of coronary artery bypass surgery. METHODS: The background information was collected by reviewing the hospital database. To assess the level of miR-155, quantitative reverse transcriptase-polymerase chain reaction was set up using the Taq Polymerase plus PacMan (TaqMan) Assay kit. To evaluate the outcomes after surgery, patients were asked by telephone calls. RESULTS: The mean miR-155 expression value in the patients with one, two, and three involved coronaries was 1.57 ± 0.21, 1.27 ± 0.28, and 1.23 ± 0.29 respectively indicating a lower level of expression in those with three-vessel disease as compared to other disease subgroups. The Gensini score was adversely associated with the level of miR-155 expression. The miR-155 expression level in patients who died in the hospital was significantly lower than in surviving patients. The presence of long-term major cardiovascular adverse events was associated with a lower level of miR-155 expression. These findings were also obtained after adjusting for background factors. CONCLUSION: Decreased expression of the miR-155 is associated with increased risk of mortality and long-term complications after coronary artery bypass surgery. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12055-025-02016-4.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。